Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 12/20 | 0.80 |
| ▸ | TNF | P01375 | 6/20 | 0.64 |
| ▸ | MAPK12 | P53778 | 3/20 | 0.64 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.64 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.64 |
| ▸ | DDR2 | Q16832 | 4/20 | 0.63 |
| ▸ | HCK | P08631 | 2/20 | 0.60 |
| ▸ | CIT | O14578 | 1/20 | 0.60 |
| ▸ | MUSK | O15146 | 1/20 | 0.60 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.60 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.60 |
| ▸ | STK10 | O94804 | 1/20 | 0.60 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.60 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.60 |
| ▸ | ABL1 | P00519 | 1/20 | 0.60 |
| ▸ | EGFR | P00533 | 1/20 | 0.60 |
| ▸ | RAF1 | P04049 | 1/20 | 0.60 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.60 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.60 |
| ▸ | PRKCB | P05771 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3184676 | 0.89 | MAPK14 (1.00) | MAPK14MAPK12MAPK13MAPK11DDR2 | |
| SCHEMBL3174378 | 0.84 | MAPK14 (0.78) | MAPK14MAPK12MAPK13MAPK11DDR2 | |
| SCHEMBL3296317 | 0.82 | MAPK14 (0.66) | MAPK14TNFMAPK12MAPK13MAPK11 | |
| SCHEMBL13481537 | 0.82 | MAPK14 (0.74) | MAPK14MAPK12MAPK13MAPK11DDR2 | |
| SCHEMBL18295958 | 0.82 | MAPK14 (0.87) | MAPK14TNFMAPK12MAPK13MAPK11 | |
| SCHEMBL29594066 | 0.81 | MAPK14 (0.78) | MAPK14TNFMAPK12MAPK13MAPK11 | |
| SCHEMBL295388 | 0.81 | MAPK14 (0.78) | MAPK14TNFMAPK12MAPK13MAPK11 | |
| SCHEMBL29593610 | 0.81 | MAPK14 (0.86) | MAPK14TNFMAPK12MAPK13MAPK11 | |
| SCHEMBL296890 | 0.81 | MAPK14 (0.86) | MAPK14TNFMAPK12MAPK13MAPK11 | |
| SCHEMBL3189772 | 0.81 | MAPK14 (0.74) | MAPK14MAPK12MAPK13MAPK11DDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7737283-B2 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC (US) | 2010-06-15 | — | — | US | disclosed |
| US-7737283-B2 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC (US) | 2010-06-15 | — | — | US | disclosed |
| US-7737283-B2 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC (US) | 2010-06-15 | — | — | US | disclosed |
| US-7666895-B2 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC (US) | 2010-02-23 | — | — | US | disclosed |
| US-7666895-B2 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC (US) | 2010-02-23 | — | — | US | disclosed |
| US-7666895-B2 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC (US) | 2010-02-23 | — | — | US | disclosed |
| US-20090312349-A1 | ANTI-INFLAMMATORY MEDICAMENTS | DECIPHERA PHARMACEUTICALS, LLC | 2009-12-17 | — | — | US | disclosed |
| US-20090312349-A1 | ANTI-INFLAMMATORY MEDICAMENTS | DECIPHERA PHARMACEUTICALS, LLC | 2009-12-17 | — | — | US | disclosed |
| US-20090312349-A1 | ANTI-INFLAMMATORY MEDICAMENTS | DECIPHERA PHARMACEUTICALS, LLC | 2009-12-17 | — | — | US | disclosed |
| EP-1836173-A4 | ANTI-INFLAMMATORY MEDICAMENTS | DECIPHERA PHARMACEUTICALS LLC (US) | 2009-07-08 | — | — | EP | disclosed |
| US-20070037808-A1 | p38 kinase inhibitors | DECIPHERA PHARMACEUTICALS, LLC | 2007-02-15 | — | — | US | disclosed |
| US-20070037808-A1 | p38 kinase inhibitors | DECIPHERA PHARMACEUTICALS, LLC | 2007-02-15 | — | — | US | disclosed |
| US-7144911-B2 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS LLC (US) | 2006-12-05 | — | — | US | disclosed |
| WO-2006081034-A2 | ANTI-INFLAMMATORY MEDICAMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2006-08-03 | — | — | WO | disclosed |
| CN-1756849-A | Modulation of protein functionality | DECIPHERA PHARMACEUTICALS LLC (US) | 2006-04-05 | — | — | CN | disclosed |
| US-20050288286-A1 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC | 2005-12-29 | — | — | US | disclosed |
| EP-1585827-A2 | MODULATION OF PROTEIN FUNCTIONALITIES | Deciphera Pharmaceuticals, LLC (US) | 2005-10-19 | — | — | EP | disclosed |
| US-20040180906-A1 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC | 2004-09-16 | — | — | US | disclosed |
| US-20040171075-A1 | Modulation of protein functionalities | DECIPHERA PHARMACEUTICALS, LLC | 2004-09-02 | — | — | US | disclosed |
| WO-2004061084-A2 | MODULATION OF PROTEIN FUNCTIONALITIES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2004-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037808-A1 | p38 kinase inhibitors | MAPK1, MAP3K8, MAP3K1 | MAPK14 29/4885TNF 102/4885MAPK12 37/4885 |
| US-20050288286-A1 | Anti-inflammatory medicaments | MIF, PTGES2, TNF | MAPK14 56/4885TNF 3/4885MAPK12 77/4885 |
| US-20090312349-A1 | ANTI-INFLAMMATORY MEDICAMENTS | ABL2, ABL1, PTK2 | MAPK14 80/4885TNF 69/4885MAPK12 118/4885 |
| US-20040180906-A1 | Anti-inflammatory medicaments | MIF, PTGES2, TNF | MAPK14 56/4885TNF 3/4885MAPK12 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.